Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid

Neuroscience Letters

Volumn 418, Issue 2, 2007, Pages 122-126

  Knyihár Csillik, Elizabeth ^a   Toldi, József ^a   Krisztin Péva, Beata ^a   Chadaide, Zoltán ^a   Németh, Hajnalka ^a   Fenyo, Robert ^a   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

c fos; Caudal trigeminal nucleus; Electrical stimulation; Immunohistochemistry; Kynurenine; Probenecid

Indexed keywords

EXCITATORY AMINO ACID; KYNURENIC ACID; KYNURENINE; KYNURENINE AMINOTRANSFERASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROBENECID; PROTEIN C FOS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN NERVE CELL; CONTROLLED STUDY; ELECTROSTIMULATION; ENZYME ACTIVITY; IMMUNOREACTIVITY; INHIBITION KINETICS; MALE; MIGRAINE; NERVE STIMULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY NERVE CELL; SYNAPSE; THALAMUS; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION;

ADJUVANTS, PHARMACEUTIC; AFFERENT PATHWAYS; ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ELECTRIC STIMULATION; IMMUNOHISTOCHEMISTRY; KYNURENINE; MALE; MIGRAINE DISORDERS; NEURONS, AFFERENT; NITROGLYCERIN; NOCICEPTORS; PROBENECID; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME; TRIGEMINAL CAUDAL NUCLEUS; VASODILATOR AGENTS;

EID: 34247343347     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.03.007     Document Type: Article

References (29)

1. Alkondon M., Pereira E.F., Yu P., Arruda E.Z., Almeida L.E., Guidetti P., Fawcett W.P., Sapko M.T., Randall W.R., Schwarcz R., Tagle D.A., and Albuquerque E.X. Targeted deletion of the kynurenine aminotransferase II gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha 7 nicotinic receptors in the hippocampus. J. Neurosci. 24 (2004) 4635-4648
2. Arulmani U., Gupta S., VanDenBrink A.M., Centurion D., Villalon C.M., and Saxena P.R. Experimental migraine models and their relevance in migraine therapy. Cephalalgia 26 (2006) 642-659
3. Battaglia G., LaRussa M., Bruno V., Arenare L., Ippolito R., Copani A., Bonina F., and Nicoletti F. Systemically administered d-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsive activity in rodents. Brain Res. 860 (2000) 149-156
4. Bullitt E. Expression of c-fos-like protein as a marker for neuronal activity following noxious stimulation in the rat. J. Comp. Neurol. 296 (1990) 517-530
5. Classey J.D., Knight Y.E., and Goadsby P.J. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. Brain Res. 907 (2001) 117-124
6. Du F., Schmidt W., Okuno E., and Schwarcz R. Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J. Comp. Neurol. 321 (1992) 477-487
7. Filla S.A., Winter M.A., Johnson K.W., Bleakman D., Bell M.G., Bleisch T.J., Castano A.M., Clemens-Smith A., del Prado M., Diekman D.K., Dominguez E., Escribano A., Ho K.H., Hudziak K.J., Katofiasc M.A., Martinez-Perez J.A., Mateo A., Mathes B.M., Mattiuz E.L., Phebus A.M., Stack D.R., Stratford R.E., and Ornstein P.L. Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycarbonylimidazol-1-nosylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. J. Med. Chem. 45 (2002) 4383-4386
8. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., and Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56 (1991) 2007-2017
9. Goadsby P.J., and Classey J.D. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 875 (2000) 119-124
10. Han Q., Li J., and Li J. pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I. Eur. J. Biochem. 271 (2004) 4804-4814
11. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., and Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha 7 nicotinic receptor activity and increases non-alpha 7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21 (2001) 7463-7473
12. Hunt S.P., Pini A., and Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 328 (1987) 632-634
13. Knyihár-Csillik E., Tajti J., Samsam M., Sáry G., Slezák S., and Vécsei L. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J. Neurosci. Res. 48 (1997) 449-464
14. Knyihár-Csillik E., Toldi J., Mihály A., Krisztin-Páva B., Chadaide Z., Németh H., Fenyo{combining double acute accent} R., and Vécsei L. Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J. Neural Transm. (2006 Aug 10) Epub ahead of print
15. Menetrey D., Gannon A., Levine J.D., and Basbaum A.I. Expression of c-fos protein in interneurons and projection neurons of the rat spinal cord in response to noxious somatic, articular, and visceral stimulation. J. Comp. Neurol. 285 (1989) 177-195
16. Miller J.M., MacGarvey U., and Beal M.F. The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. Neurosci. Lett. 146 (1992) 115-118
17. Mitsikostas D.D., and Sanchez del Rio M. Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res. Brain Res. Rev. 35 (2001) 20-35
18. Mitsikostas D.D., Sanchez del Rio M., Waeber C., Moskowitz M.A., and Cutrer F.M. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 76 (1988) 239-248
19. Molander C., Hongpaisan J., and Grant G. Changing pattern of c-fos expression in spinal cord neurons after electrical stimulation of the chronically injured sciatic nerve in the rat. Neuroscience 50 (1992) 223-236
20. Morgan J.I., and Curran T. Role of ion flux in the control of c-fos expression. Nature 322 (1986) 552-555
21. Moroni F., Russi P., Lombardi G., Beni M., and Carla V. Presence of kynurenic acid in the mammalian brain. J. Neurochem. 51 (1988) 177-180
22. Németh H., Robotka H., Kis Z., Rózsa E., Janáky T., Somlai C., Marosi M., Farkas T., Toldi J., and Vécsei L. Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioral study. Neuropharmacology 47 (2004) 916-925
23. Robotka H., Németh H., Somlai C., Vécsei L., and Toldi J. Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. Eur. J. Pharmacol. 513 (2005) 75-80
24. Schwarcz R., and Pellicciari R. Manipulation of brain kynurenine: glial targets, neuronal effects and clinical opportunities. J. Pharmacol. Exp. Ther. 303 (2002) 1-10
25. Stone T.W., and Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1 (2002) 609-620
26. Vécsei L., Miller J., MacGarvey U., and Beal M.F. Effects of kynurenine and probenecid on plasma and brain tissue concentration of kynurenic acid. Neurodegeneration 1 (1992) 17-26
27. Vécsei L., Miller J., MacGarvey U., and Beal M.F. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentration in the brain. Brain Res. Bull. 28 (1992) 233-238
28. Weiss B., Alt A., Ogden A.M., Gates M., Dieckman D.K., Clemens-Smith A., Ho K.H., Jarvie K., Rizkalla G., Wright R.A., Calligaro D.O., Schoepp D., Mattiuz E.L., Stratford R.E., Johnson B., Salhoff C., Katofiasc M., Phebus L.A., Schenck K., Cohen M., Filla S.A., Ornstein P.L., Johnson K.W., and Bleakman D. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J. Pharmacol. Exp. Ther. 318 (2006) 772-781
29. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. TINS 22 (1999) 51-61